JP2003520015A - 体重およびそれに関連する状態を調節する組成物および方法 - Google Patents

体重およびそれに関連する状態を調節する組成物および方法

Info

Publication number
JP2003520015A
JP2003520015A JP2000586172A JP2000586172A JP2003520015A JP 2003520015 A JP2003520015 A JP 2003520015A JP 2000586172 A JP2000586172 A JP 2000586172A JP 2000586172 A JP2000586172 A JP 2000586172A JP 2003520015 A JP2003520015 A JP 2003520015A
Authority
JP
Japan
Prior art keywords
animal
compound
pomc
melanocortin
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000586172A
Other languages
English (en)
Japanese (ja)
Inventor
ビー． ブレナン、マイルズ
ホーフゲシュヴェンダー、ウーテ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/374,827 external-priority patent/US6603058B1/en
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of JP2003520015A publication Critical patent/JP2003520015A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000586172A 1998-12-09 1999-12-09 体重およびそれに関連する状態を調節する組成物および方法 Pending JP2003520015A (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US11158198P 1998-12-09 1998-12-09
US60/111,581 1998-12-09
US14630499P 1999-07-29 1999-07-29
US14630699P 1999-07-29 1999-07-29
US14630599P 1999-07-29 1999-07-29
US14630199P 1999-07-29 1999-07-29
US14630399P 1999-07-29 1999-07-29
US14629999P 1999-07-29 1999-07-29
US14630099P 1999-07-29 1999-07-29
US14630299P 1999-07-29 1999-07-29
US60/146,299 1999-07-29
US60/146,303 1999-07-29
US60/146,305 1999-07-29
US60/146,300 1999-07-29
US60/146,302 1999-07-29
US60/146,306 1999-07-29
US60/146,304 1999-07-29
US60/146,301 1999-07-29
US09/374,827 US6603058B1 (en) 1998-12-09 1999-08-12 Non-human animal model for obesity and uses thereof
US09/374,827 1999-08-12
PCT/US1999/029337 WO2000033658A1 (en) 1998-12-09 1999-12-09 Composition and method for regulation of body weight and associated conditions

Publications (1)

Publication Number Publication Date
JP2003520015A true JP2003520015A (ja) 2003-07-02

Family

ID=27581011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000586172A Pending JP2003520015A (ja) 1998-12-09 1999-12-09 体重およびそれに関連する状態を調節する組成物および方法

Country Status (6)

Country Link
EP (1) EP1137340A4 (es)
JP (1) JP2003520015A (es)
AU (1) AU3117600A (es)
CA (1) CA2353776A1 (es)
MX (1) MXPA01005818A (es)
WO (1) WO2000033658A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517605A (ja) * 2004-10-25 2008-05-29 セントカー・インコーポレーテツド メラノコルチン受容体結合性ミメティボディ、組成物、方法および用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2406755A1 (en) * 2000-04-28 2001-11-08 Zengen Inc. A gene therapy system and method using alpha-msh and its derivatives
EP1303625A2 (en) 2000-07-14 2003-04-23 Zycos Inc. Alpha-msh related compounds and methods of use
EP1322954A4 (en) * 2000-09-13 2005-08-03 Eleanor Roosevelt Inst METHOD FOR TREATING INSULIN RESISTANCE IN OVERWEIGHT AND DIABETES
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
JP2006527773A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン受容体４（ｍｃ４）作用薬とその用途
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
FR2857873B1 (fr) * 2003-07-21 2006-02-24 Courtage Et De Diffusion Codif Procede et produit cosmetique destines a limiter la croissance des tissus adipeux
EP1732586A1 (en) * 2004-03-29 2006-12-20 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion
BRPI0508787A (pt) * 2004-04-08 2007-09-04 Astellas Pharma Inc composto ws727713, cepa de actinomiceto, composto com atividade moduladora de receptor de melanocortina, processo para produzir o composto ws727713, modulador de receptor de melanocortina, uso do composto e composição farmacêutica
WO2005118573A1 (en) 2004-05-28 2005-12-15 Smithkline Beecham Corporation Novel diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors
US7169773B2 (en) 2004-07-01 2007-01-30 Smithkline Beecham Corporation Compounds
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
WO2006073771A2 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US7790671B2 (en) 2005-10-07 2010-09-07 Codman & Shurtleff, Inc. Implantable pump for protein delivery for obesity control by drug infusion into the brain
AU2009248914A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for Treating Neurodegenerative Disorders Related to Neurofibrillary Tangles
CA2742600A1 (en) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100048A (en) * 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517605A (ja) * 2004-10-25 2008-05-29 セントカー・インコーポレーテツド メラノコルチン受容体結合性ミメティボディ、組成物、方法および用途

Also Published As

Publication number Publication date
EP1137340A1 (en) 2001-10-04
AU3117600A (en) 2000-06-26
CA2353776A1 (en) 2000-06-15
EP1137340A4 (en) 2005-12-21
MXPA01005818A (es) 2003-07-21
WO2000033658A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
US20060063708A1 (en) Composition and method for regulation of body weight and associated conditions
Tao The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology
US7186694B2 (en) Leptin-related peptides
Meunier Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor
US7790683B2 (en) Leptin-related peptides
US20030144174A1 (en) Methods for identifying compounds useful for the regulation of body weight and associated conditions
JP2003520015A (ja) 体重およびそれに関連する状態を調節する組成物および方法
US20080207543A1 (en) Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
US6689938B2 (en) Method for treatment of insulin resistance in obesity and diabetes
WO2004039832A2 (en) Leptin-related peptides
Tao Mutations in melanocortin-4 receptor: From fish to men
EP2612678B1 (en) Screening method for antidiabetic agent using newly identified insulin secretion regulation factor
CN101505786A (zh) 涉及能量内稳态的新肽
KR20050042826A (ko) 쥐피알54 넉-아웃 포유류 및 이를 이용한 스크리닝 방법
RU2273645C2 (ru) Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело
US6603058B1 (en) Non-human animal model for obesity and uses thereof
US20060156423A1 (en) Method of screening antiobesity agents and animal model of obesity
Fang et al. Development of a transgenic mouse that overexpresses a novel product of the growth hormone-releasing hormone gene
TWI250209B (en) A novel G protein-coupled receptor, GAVE8
US20120079613A1 (en) Homeobox Transcription Factor BSX and Uses Thereof for Treating Diseases, in Particular Obesity
BRPI9508596B1 (pt) polipeptídeos de obesidade (ob), composição compreendendo os mesmos, bem como vetores para expressão dos referidos polipeptídeos

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110303

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120522